Articles tagged with Cell Therapies
Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...
Researchers at Nagoya University developed a unique supramolecule to remove cholesterol from macrophages, stopping the development of non-alcoholic steatohepatitis (NASH) in mice. Cholesterol crystals are also found in human patients, suggesting a potential therapeutic strategy.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers have identified novel therapeutic targets using single-cell and spatially resolved omics, including cannabidiol for colorectal tumors, Cux1 as a potential target for dry skin diseases, and microglia communication for Alzheimer's disease. These studies offer hope for future treatments.
Researchers developed a technology to rapidly screen genetic edits in immune cells, identifying a new combination that improves their effectiveness against cancers. By combining multiple genes into long DNA stretches and testing thousands of combinations, scientists discovered that different CARs can be optimized by different factors.
Researchers at NYU Abu Dhabi have developed acidity-triggered rational membrane peptide-functionalized nanospheres that combine tumor detection and monitoring with potent, light-triggered cancer therapy. These nanospheres enable improved efficacy of phototherapies with minimal systemic toxicity.
Brigham researchers discovered a nasal immunotherapy approach that reduces inflammation and improves cognitive function in Alzheimer's mouse models. The treatment also expands regulatory T cells and changes gene expression patterns in the brain.
Age-related macular degeneration (AMD) decreases essential fatty acid docosahexaenoic acid (DHA), limiting protective molecule formation and repair potential. The discovery may open new therapeutic avenues for AMD, particularly in females, who are more susceptible to retinal degeneration due to estrogen effects.
Researchers have found that the protein Musashi-2 plays a crucial role in regulating type 2a muscle fiber mass and metabolism. The study reveals that Msi2 knockout mice exhibit reduced muscle mass, decreased myoglobin and mitochondria levels, and impaired sugar metabolism.
A randomized trial published in The Lancet Oncology found that condensing prostate beam scanning proton therapy for breast cancer patients can result in similar control of the cancer while sparing surrounding normal tissue. The study demonstrated excellent outcomes, with reduced skin side effects and comparable complication rates.
Researchers at Hollings Cancer Center have made a breakthrough in CAR-T-cell therapy by eliminating the need for lymphodepleting chemotherapy, which reduces the risk of severe side effects. In preclinical models, their method showed promising results in controlling cancer and creating memory cells trained on specific proteins.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
A newly discovered fungus has been found to transform the toxic compound patulin into less harmful byproducts, offering potential solutions for controlling its presence in food products. The fungus, identified as Acremonium sp., was shown to degrade patulin into desoxypatulinic acid and other compounds, which are significantly less toxic.
A new oral agent called mezigdomide has shown impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies. The treatment produced a response rate of over 40% and a median duration of response of almost 8 months.
Scientists engineer bacteria to target cancer cells, utilizing NIR fluorescence and photothermal conversion to selectively eliminate malignant cells. The study demonstrates effective optical and immunological functions in a mouse model of colon cancer.
Researchers at Cold Spring Harbor Laboratory have made a significant breakthrough in transforming rhabdomyosarcoma cells into regularly functioning muscle cells using differentiation therapy. This innovative approach has the potential to spare patients and their families from pain and suffering by offering a new treatment option.
Researchers have engineered an AAV vector to target brain vascular pericytes and smooth muscle cells, potentially treating conditions like Alzheimer's disease and Parkinson's. This breakthrough could revolutionize gene therapy by delivering genes directly to the brain's blood vessels.
The CABINET trial showed statistically significant and clinically meaningful improvements in progression-free survival for patients with pancreatic and extra-pancreatic neuroendocrine tumors. The study also demonstrated a consistent safety profile for cabozantinib, with no new safety signals identified.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Recent research on gamma delta T cells has made significant progress in understanding their role in antitumor immune response. Key findings include the identification of various hidden mechanisms and a strong association between tumor-infiltrating gamma delta T cells and patient survival.
Researchers have identified a neoplastic fusion transcript RAD51AP1-DYRK4 in luminal B breast cancer, associated with higher ki67 expression and aggressive clinical characteristics. MEK inhibitor trametinib may be effective in blocking the MEK-ERK signaling driven by this fusion.
A novel CRISPR-based gene-editing treatment, EBT-001, effectively removes SIV from the genomes of non-human primates without off-target effects. The study's findings support the development of a cure for HIV/AIDS in humans and pave the way for ongoing clinical trials.
Glutamine metabolism plays a crucial role in cancer cell growth and survival, with its inhibition shown to block cancer cell growth in vivo and in vitro. A recent editorial paper suggests that glutamine dysregulation may also impact the tumor microenvironment, potentially leading to increased oxidative stress and cancer cell death.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
Researchers have identified a therapeutic target for Alzheimer's disease by finding that inhibiting an ion pump can slow down cognitive decline and partially restore brain function. The study's findings suggest that maintaining the ion pump could be key to preventing or reversing the disease.
LSU Health researchers found combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases effectiveness in experimental models of ER+ and TNBC. The study's findings suggest a new approach for treating treatment-resistant breast cancers.
Researchers at Brigham and Women's Hospital have designed a probiotic to suppress autoimmunity in the brain, which is at the core of several diseases including MS. The treatment offers a more precise way to target brain inflammation with reduced negative side effects compared to standard therapies.
Researchers explore CDK9 inhibitors as a promising combination partner in treating hematological malignancies. They discuss the role of cyclin-dependent kinases (CDKs) in these diseases and highlight the potential synergism with other drugs.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers highlight the need for effective treatment strategies for adenoid cystic carcinoma (ACC) of the head and neck, which is a highly malignant tumor with variable localizations. Proton therapy shows decisive advantages in long-term survival rates for ACC.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
Researchers have identified a novel therapeutic target for pelvic pain in endometriosis by focusing on the IL-1β pathway and its regulation via the JNK signaling pathway. This study suggests that JNK inhibitors may be effective in reducing neuroinflammation and alleviating symptoms of endometriosis-associated pain.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
Targeting tiny amounts of hydrogen sulfide to specific areas of cells in adult worms improved health and activity as they aged, according to a University of Exeter study. The research found that H2S improved the integrity of mitochondria, kept muscles active, and extended lifespan.
A new review paper suggests scrambler therapy can yield significant relief for approximately 80-90% of patients with chronic pain. The therapy works by capturing nerve endings and replacing pain signals with signals from adjacent areas, 'scrambling' the pain signals sent to the brain.
A team of researchers at the University of Oklahoma has made a groundbreaking discovery in overcoming antimicrobial resistance by developing a new class of molecules that inhibit efflux pumps. These inhibitors work as 'molecular wedges' targeting the area between bacterial cell membranes, increasing the effectiveness of antibiotics.
Researchers found that Alzheimer's patients exhibit heightened sensitivity to light changes, which can contribute to 'sundowning' and disease progression. Light therapy could help manage these symptoms and potentially slow disease progression.
Researchers have identified KIAA0930 as a key factor causing muscle atrophy in cancer cells, which could lead to the development of new anti-cachexia therapies. The study found that KIAA0930 knockdown cells showed increased muscle mass and weight compared to control cells.
Researchers at Sahmyook University repurposed meclofenamate to treat abnormal respiratory mucus, reducing mucin secretion and characteristics of respiratory mucus. This study offers an alternative solution for patients with respiratory diseases, saving time and costs compared to conventional drug development strategies.
Researchers at UCL and Stanford University create a three-component anti-cancer therapy using click chemistry, improving cancer-killing efficiency with sialidase enzyme, and exploring potential for next-generation agents.
Dr. Beau Webber received a two-year Translation to CURE award to study genetically engineered gamma delta T cells for treating metastatic osteosarcoma. This innovative approach aims to address the limitations of current immune-cell based therapies and offers new hope for childhood cancer treatment.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
Researchers found that BUB1 protein regulates EGFR signaling by reducing receptor internalization, which may lead to new therapeutic interventions for EGFR-driven cancers. The study also showed that BUB1 impacts receptor recycling and degradation, affecting signaling amplitude and duration.
Researchers have discovered a way to identify pregnant women at risk of preeclampsia by examining lipids in their blood during pregnancy. The approach worked regardless of whether the women were on aspirin therapy, and could predict the risk of preeclampsia with significant accuracy.
A novel biomaterials-based approach enhances adoptive T cell therapy with cancer vaccine technology, providing strong and long-lasting effects against solid tumors. In mice carrying melanomas, SIVET enables fast tumor shrinking and long-term protection.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Mass General Cancer Center researchers have pinpointed the APOBEC3A protein as a primary driver of drug resistance in non-small-cell lung cancer. The study reveals that this protein causes mutations and accelerates tumor growth, making it a promising target for new therapies.
Mass General Brigham researchers have made key improvements to Parkinson's disease cell therapies by using regulatory T cells to supplement neuronal cell therapy. The study shows that co-transplanting regulatory T cells with dopaminergic neurons increases survival and improves behavior recovery in rodent models.
A new study reveals that preoperative hydroxyprogesterone administration can improve disease-free and overall survival in patients with node-positive breast cancer by modulating cellular stress response and negative regulation of inflammation. Non-coding RNAs, such as DSCAM-AS1, play a regulatory role in this process.
Researchers at St. Jude Children's Research Hospital created a more accurate hepatoblastoma model to improve therapies, focusing on DNA damage repair pathways. The model identified potential targets and validated the effectiveness of PRKDC inhibition when combined with doxorubicin, enhancing treatment efficacy.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
A team from the University of Ottawa has developed a comprehensive screening platform and cellular interrogation tool to facilitate novel drug discovery targeting various human diseases. The 'Tango-Trio' platform can identify small molecule modulators for orphan GPCRs, which have significant untapped therapeutic potential.
St. Jude researchers found that supplying glutamine to tumors enhances the immune system's cancer-killing activity, while a molecular pathway identified as a potential drug target could improve anti-cancer therapies. Glutamine helps activate dendritic cells, which then activate T cells that kill cancer cells.
A new study describes an engineered approach that makes protein aggregates amenable to spatial manipulations in both budding yeast and human cells. This system allows for the export of protein aggregates from cells, potentially protecting mother cells from toxicity and contributing to a better understanding of neurodegenerative diseases.
A research team from HKUMed has developed a new platform to rapidly engineer and select the best precise genome editors for therapeutic applications. The platform allows for parallel testing of hundreds of base editor variants, enabling the selection of the most suitable ones with maximal efficiency and minimal undesired edits.
Researchers investigated premature senescence in biliary atresia and assessed senotherapies. They found that human allogenic liver-derived progenitor cells reduced early markers of senescence and improved liver disease in a preclinical model, providing encouraging results for pediatric biliary cirrhosis treatment.